JP2023103455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023103455A5 JP2023103455A5 JP2023083756A JP2023083756A JP2023103455A5 JP 2023103455 A5 JP2023103455 A5 JP 2023103455A5 JP 2023083756 A JP2023083756 A JP 2023083756A JP 2023083756 A JP2023083756 A JP 2023083756A JP 2023103455 A5 JP2023103455 A5 JP 2023103455A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- seq
- fgf21
- mutations
- fgf21 polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529215P | 2017-07-06 | 2017-07-06 | |
| US62/529,215 | 2017-07-06 | ||
| JP2019572539A JP7316946B2 (ja) | 2017-07-06 | 2018-07-05 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572539A Division JP7316946B2 (ja) | 2017-07-06 | 2018-07-05 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023103455A JP2023103455A (ja) | 2023-07-26 |
| JP2023103455A5 true JP2023103455A5 (https=) | 2024-04-12 |
Family
ID=64950347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572539A Active JP7316946B2 (ja) | 2017-07-06 | 2018-07-05 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
| JP2023083756A Pending JP2023103455A (ja) | 2017-07-06 | 2023-05-22 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572539A Active JP7316946B2 (ja) | 2017-07-06 | 2018-07-05 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11365228B2 (https=) |
| EP (1) | EP3649157A4 (https=) |
| JP (2) | JP7316946B2 (https=) |
| CN (1) | CN110997726B (https=) |
| AU (1) | AU2018297285A1 (https=) |
| CA (1) | CA3069143A1 (https=) |
| WO (1) | WO2019010314A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| HK1214832A1 (zh) | 2012-11-28 | 2016-08-05 | 恩格姆生物制药公司 | 用於代謝病症和疾病治療的組合物和方法 |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| MX383664B (es) | 2012-12-27 | 2025-03-14 | Ngm Biopharmaceuticals Inc | Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares. |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| CN111420030B (zh) * | 2020-05-12 | 2021-01-29 | 江南大学 | Fgf21在制备用于治疗结直肠癌药物中的应用 |
| WO2021231720A1 (en) * | 2020-05-15 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
| CN113735959B (zh) * | 2021-03-12 | 2023-07-04 | 江南大学 | 一种治疗nash的fgf类似物 |
| CN113105561B (zh) * | 2021-04-30 | 2021-12-03 | 江南大学 | 一种双靶点融合蛋白的制备方法和应用 |
| WO2025059130A1 (en) * | 2023-09-11 | 2025-03-20 | Yale University | Constructs for modulating fgf21/fgfr/beta-klotho signaling pathway and treating diseases and disorders, and methods thereof |
| CN118852466B (zh) * | 2024-08-08 | 2025-03-28 | 郑州大学第三附属医院(河南省妇幼保健院) | Klotho修饰的CAR-T结构及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| SI2550972T1 (en) | 2007-04-02 | 2018-05-31 | Genentech, Inc. | A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| EP2296690B1 (en) | 2008-06-04 | 2016-11-30 | Amgen, Inc | Fgf21 mutants and uses thereof |
| EP2427207B1 (en) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
| US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| CA2796055A1 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | Human fgf receptor and .beta.-klotho binding proteins |
| JP5927782B2 (ja) | 2010-06-15 | 2016-06-01 | 国立大学法人広島大学 | 石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途 |
| MX2013013044A (es) | 2011-05-10 | 2014-02-20 | Amgen Inc | METODO PARA IDENTIFICAR COMPUESTOS QUE ESPECIFICAMENTE MODULAN LA INTERACCION DE FGFR1 Y ß-KLOTHO. |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| WO2013027191A1 (en) | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
| US9475856B2 (en) * | 2012-03-02 | 2016-10-25 | New York University | Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
| US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
| US9400677B2 (en) | 2013-01-02 | 2016-07-26 | Apple Inc. | Adaptive handling of priority inversions using transactions |
| US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| AU2015237176A1 (en) | 2014-03-28 | 2016-10-20 | New York University | FGF23 fusion proteins |
| CN107810201A (zh) | 2014-12-04 | 2018-03-16 | 诺华股份有限公司 | 使用klotho变体多肽的方法和组合物 |
| WO2016204884A1 (en) | 2015-06-18 | 2016-12-22 | Albert Einstein College Of Medicine, Inc. | Fgf receptor ligands for treating diabetes and obesity |
| EP3371217B1 (en) * | 2015-11-08 | 2025-06-11 | F. Hoffmann-La Roche AG | Methods of screening for multispecific antibodies |
| WO2017180988A2 (en) * | 2016-04-15 | 2017-10-19 | Indiana University Research And Technology Corporation | Fgf21 c-terminal peptide optimization |
| CA3026510A1 (en) | 2016-05-25 | 2017-11-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of secretory disorders |
| WO2018026899A1 (en) | 2016-08-03 | 2018-02-08 | Joslin Diabetes Center, Inc. | Methods and compositions for treating hypoglycemia |
-
2018
- 2018-07-05 AU AU2018297285A patent/AU2018297285A1/en not_active Abandoned
- 2018-07-05 CN CN201880054775.3A patent/CN110997726B/zh active Active
- 2018-07-05 JP JP2019572539A patent/JP7316946B2/ja active Active
- 2018-07-05 CA CA3069143A patent/CA3069143A1/en active Pending
- 2018-07-05 US US16/624,895 patent/US11365228B2/en active Active
- 2018-07-05 EP EP18827563.0A patent/EP3649157A4/en active Pending
- 2018-07-05 WO PCT/US2018/040932 patent/WO2019010314A1/en not_active Ceased
-
2023
- 2023-02-28 US US18/176,172 patent/US12534503B2/en active Active
- 2023-05-22 JP JP2023083756A patent/JP2023103455A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023103455A5 (https=) | ||
| RU2729161C2 (ru) | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения | |
| JP7761557B2 (ja) | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 | |
| KR102077721B1 (ko) | 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법 | |
| JP2020526503A5 (https=) | ||
| US10617741B2 (en) | Compositions and methods for oral delivery of therapeutic cargo | |
| KR20070004078A (ko) | 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도 | |
| JP2017531613A (ja) | 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 | |
| JP2005507637A5 (https=) | ||
| CN105189542A (zh) | 用于治疗庞贝氏症的方法和组合物 | |
| JPWO2019157224A5 (https=) | ||
| JP7479539B2 (ja) | インターロイキン－２２の治療用誘導体 | |
| JP2010514699A (ja) | インスリン感受性および脂質プロファイルを改善するための長時間作用型ｇｌｐ−１受容体アゴニストの使用 | |
| KR20090039787A (ko) | 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도 | |
| JP2017519039A (ja) | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 | |
| JP2023546090A (ja) | Ｇｌｐ－１／ｇｉｐ二重作用剤、その持続型結合体、及びそれを含む薬学的組成物 | |
| JP2019527053A (ja) | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 | |
| CN117597357A (zh) | 白细胞介素-22的治疗性衍生物 | |
| EP4337681A1 (en) | Therapeutic derivatives of interleukin-22 | |
| CN117616035A (zh) | 白介素-22的治疗性衍生物 | |
| CN116635050A (zh) | 对胰高血糖素、glp-1和gip受体全部具有活性的新型三重激动剂及其用途 | |
| JP2009517009A5 (https=) | ||
| RU2685867C2 (ru) | Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты) | |
| WO2008003748A2 (en) | Cd300lg polypeptides and their use in treating autoimmune diseases | |
| KR20220010462A (ko) | 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도 |